Avulux Migraine Glasses

Avulux is the first product in a brand new FDA device category, cleared through De Novo rather than the usual 510(k) route.

Amrit Bance

3 min read

Avulux Migraine Glasses

What Kind of Approval?

Avulux is the first product in a brand new FDA device category, cleared through De Novo rather than the usual 510(k) route. The 510(k) route borrows credibility from something already on the market. De Novo is for devices with nothing on the market to compare it to, so FDA built a category from scratch, and Avulux's authorisation now becomes the benchmark for everyone else in the space.

Not Polarised, Filtered

Polarised lenses block light by angle and let the full colour spectrum through. Avulux blocks by wavelength instead: two narrow bands, 480nm blue and 590nm amber, tied to migraine pain.

Didn’t Meet Expectations, Got Authorised Anyway, What a Boss.

The pivotal 78-person trial missed its own primary goal, no real difference in pain relief at two or four hours. This would be a problem for a drug application. However, for these glasses it is permissible, as Class I devices only need reasonable safety plus a plausible benefit to be approved. Avulux leaned on a post-hoc subgroup and a small healthy-volunteer study, which looked at reducing discomfort from light. FDA authorised, yes. But when a trial misses its own main measure, would you wait for stronger data before recommending it to a patient?

Sources: